Drug Trial News

RSS

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.

25 Mar 2011

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.

25 Mar 2011

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide have been accepted for presentation at the National Kidney Foundation 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.

24 Mar 2011

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD®) study, published today by the New England Journal of Medicine (NEJM), demonstrate that Spiriva® (tiotropium), is superior to salmeterol, in reducing the risk of exacerbations in Chronic Obstructive Pulmonary Disease (COPD).

24 Mar 2011

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

24 Mar 2011

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

An hour can make the difference between life and death when using tranexamic acid to treat injured patients with severe bleeding, a study by researchers at the London School of Hygiene & Tropical Medicine suggests.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead Sciences, Inc. today announced that the Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective.

24 Mar 2011

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

Oramed Pharmaceuticals Inc., a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

23 Mar 2011

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

23 Mar 2011

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

ViroPharma Incorporated today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology Annual Meeting, March 18 through 22, in San Francisco, CA.

23 Mar 2011

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN® (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

23 Mar 2011

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

Although recent evidence suggests that the clinical benefit may be uncertain for fibrates, a class of drugs used for the treatment of high lipid levels, use of these drugs is common in the U.S. and Canada, with usage increasing steadily in the last decade in the U.S., especially for a brand-name fibrate product, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia

Harvest Technologies Corp. announced today that the FDA has approved the company sponsored 210-patient IDE clinical trial to be conducted at twenty-five sites in the U.S. using the company's proprietary Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI).

23 Mar 2011

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

Drug Trial News

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

MnSOD oral drug can protect against lung cancer radiation therapy

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News